Abstract: Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: A method and apparatus for injecting saline into an open cavity of a patient's body, and, alternatively, vacuuming fluids from said cavity, during laparoscopic surgery that provides constant feed and amplified pressure to provide a steady fluid output, in a disposable, single use handheld surgical device.

Abstract: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.

Abstract: Methods for treating and preventing ocular conditions by administering an compound to the vitreous chamber of a patient at risk of, or suffering from, the ocular condition.

Abstract: Convening dewatered heterogeneous sludge containing organic waste materials into a homogenous extract of carbon and amino acids for fertilizer production by adding sulfuric acid to the sludge; pumping the mixture through a blending mixer to mix the sludge with the sulfuric acid; adding conditioning chemicals to the mixture: pumping the mixture through a shearing mixer to mix the conditioning chemicals into the mixture; and mechanically agitating the mixture to create the homogenous extract. Optionally, the extract is pumped into a pipe reactor for reaction with an acid and a base to form a melt, which is rolled onto fertilizer particles to form accreted granules. The accreted granules are dried to form a granular fertilizer. Also described is an organically-enhanced granular nitrogen-phosphorous-sulfur fertilizer having at least about 0.5% by weight total carbon and amino acids, and accreted granule size greater than or equal to about 1.7 mm. The fertilizer is noncombustible.

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

Abstract: A dynamic document template contains a set of queries. Each query may include a query scope. The query scope may refer to a content of a source document that is maintained in a document collection. A content rule is applied to monitor the template for a change. A notification event is triggered when a change to the document collection results in an invalid query scope in the template. A notification event may also be triggered when a change to the document collection results in valid query but the template needs to be refreshed. An additional notification event may be triggered if the template is modified so that the resulting template is either invalid or needs to be refreshed with different content from the collection.

Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.

Abstract: A disposable device for tissue cauterization, including a generally electrically insulating housing assembly and a generally electrically conducting elongated assembly. The housing assembly includes a barrel having a cylindrical aperture formed therethrough, a grip extending from the barrel, a trigger slidingly connected to the barrel, a spring connected to the trigger, and an end plug positioned adjacent the proximal end of the barrel. The elongated assembly includes a hollow elongated outer cylinder disposed within the barrel and extending from the distal end, a generally hollow elongated inner cylinder slidably disposed within the elongated outer cylinder and extending to snugly engage the end plug, and bipolar forceps operationally connected to the distal end of the elongated inner cylinder and defining a leaf spring.

Abstract: Shroud assembly for use in a turbine, having an outer shroud having a side proximate to flow of operative fluid of the turbine, the side having a boss and an outer shroud aperture extending through the boss. An inner shroud is located between the side of the outer shroud proximate to the flow of operative fluid and the operative fluid flow of the turbine, the inner shroud having an inner shroud aperture which is dimensioned to fit over the boss.

Abstract: Particles emitted by radio-isotopic by-products of nuclear fission are used as a power source at the cathode of a magnetron system. Particles include high energy electrons having a large associated EMF. In the system a radial electrical vector E, between the cathode and anode, interacts with an axial magnetic vector B vector to produce an E×B force that rotates the particles about the system axis. These emissions are within a set range of velocities. The angular velocity and geometry of a rotating field, known as a space charge wheel (SCW), may be modulated by an external RF inputs to cavities of an anode block and the use of concentric biasing grids between the cathode and anode block. The SCW induces LC values into cavities of the anode, exciting them and producing electrons resonance which may be used to generate power.

Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.